Drug Development
The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine’s positive effects on animal memory. The development of nicotinic acetylcholine receptor agonists has come a long way since then. The nicotinic acetylcholine receptor agonist are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction. Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.
In 2009 there were at least five drugs on the market that affect the nicotinic acetylcholine receptors.
| Quinuclidine Carbamates | Quinuclidine Amides | Quinuclidine Ethers |
Read more about this topic: Nicotinic Agonist
Famous quotes containing the words drug and/or development:
“Most people aren’t appreciated enough, and the bravest things we do in our lives are usually known only to ourselves. No one throws ticker tape on the man who chose to be faithful to his wife, on the lawyer who didn’t take the drug money, or the daughter who held her tongue again and again. All this anonymous heroism.”
—Peggy Noonan (b. 1950)
“As long as fathers rule but do not nurture, as long as mothers nurture but do not rule, the conditions favoring the development of father-daughter incest will prevail.”
—Judith Lewis Herman (b. 1942)